{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:13:05Z","timestamp":1793113985381,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejca.2024.114028","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T13:54:52Z","timestamp":1711547692000},"page":"114028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors"],"prefix":"10.1016","volume":"203","author":[{"given":"Theresa","family":"Ruf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"D\u00fccker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Ertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Tomsitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K.","family":"Tietze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Dabrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Gesierich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Zierold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars E.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Eigentler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114028_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2024.114028_bib2","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","article-title":"Early use of high-dose glucocorticoid for the management of irae is associated with poorer survival in patients with advanced melanoma treated with Anti-PD-1 monotherapy","volume":"27","author":"Bai","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.114028_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2022.5041","article-title":"Association of immune-related adverse event management with survival in patients with advanced Melanoma","author":"van Not","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2024.114028_bib4","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.jtho.2021.06.024","article-title":"Beyond steroids: immunosuppressants in steroid-refractory or resistant immune-related adverse events","volume":"16","author":"Luo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2024.114028_bib5","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","article-title":"Association of Anti-TNF with decreased survival in steroid refractory Ipilimumab and Anti-PD1-treated patients in the dutch melanoma treatment registry","volume":"26","author":"Verheijden","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.114028_bib6","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.3390\/cancers15092538","article-title":"Steroid-refractory immune-related adverse events induced by checkpoint inhibitors","volume":"15","author":"Tomsitz","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2024.114028_bib7","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S1470-2045(18)30828-3","article-title":"New therapeutic perspectives to manage refractory immune checkpoint-related toxicities","volume":"20","author":"Martins","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114028_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/ajco.13332","article-title":"The role of immunosuppressive agents in the management of severe and refractory immune-related adverse events","volume":"16","author":"Wang","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114028_bib9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1056\/NEJMc1912274","article-title":"Extracorporeal photopheresis for colitis induced by checkpoint-inhibitor therapy","volume":"382","author":"Apostolova","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114028_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.dib.2022.108649","article-title":"Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis","volume":"45","author":"M\u00fcller-Jensen","year":"2022","journal-title":"Data Brief"},{"key":"10.1016\/j.ejca.2024.114028_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114028_bib12","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"0","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114028_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"NCCN clinical practice guidelines in oncology nccn categories of evidence and consensus","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2024.114028_bib14","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114028_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2024.114028_bib16","first-page":"358","article-title":"Diagnosis and management of immune checkpoint inhibitor colitis","volume":"17","author":"Hashash","year":"2021","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.ejca.2024.114028_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102595","article-title":"Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort","volume":"19","author":"Roberts","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ejca.2024.114028_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.19860","article-title":"Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid. J Eur","author":"Kramer","year":"2024","journal-title":"Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2024.114028_bib19","article-title":"Checkpoint inhibitor-induced lichen planus differs from spontaneous lichen planus on the clinical, histological and gene expression level","volume":"0","author":"Meier-Schiesser","year":"2024","journal-title":"JAAD Int"},{"key":"10.1016\/j.ejca.2024.114028_bib20","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00432-021-03550-5","article-title":"Inflammatory markers in autoimmunity induced by checkpoint inhibitors","volume":"147","author":"Husain","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114028_bib21","article-title":"The Side Effect Registry Immuno-Oncology (SERIO) \u2013 a tool for systematic analysis of immunotherapy-induced side effects","volume":"0","author":"Ertl","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114028_bib22","article-title":"Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance","volume":"7","author":"Verheijden","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.ejca.2024.114028_bib23","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114028_bib24","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2024.114028_bib25","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1136\/jitc-2022-005635","article-title":"Original research: systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events","volume":"10","author":"Coukos","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2024.114028_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CJI.0000000000000268","article-title":"Incidence and Clinical Impact of Anti-TNF\u03b1 treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: the mecolit survey.","volume":"42","author":"Lesage","year":"2019","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2024.114028_bib27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41584-021-00584-4","article-title":"TNF in the era of immune checkpoint inhibitors: friend or foe?","volume":"17","author":"Chen","year":"2021","journal-title":"Nat Rev Rheuma"},{"key":"10.1016\/j.ejca.2024.114028_bib28","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2024.114028_bib29","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2010.12.032","article-title":"Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-na\u00efve patients","volume":"55","author":"Zachou","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2024.114028_bib30","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1191\/096120301682430186","article-title":"The safety and efficacy of MMF in lupus nephritis: a pilot study","volume":"10","author":"Kingdon","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.ejca.2024.114028_bib31","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.rdc.2020.05.003","article-title":"Cancer and rheumatoid arthritis","volume":"46","author":"Pundole","year":"2020","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.ejca.2024.114028_bib32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1212\/01.wnl.0000173031.56429.04","article-title":"Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil","volume":"65","author":"Vernino","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ejca.2024.114028_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2249.2003.02199.x","article-title":"Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin","volume":"133","author":"Brennan","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ejca.2024.114028_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2024.114028_bib35","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2024.114028_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000714","article-title":"Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy","volume":"4","author":"Leipe","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.ejca.2024.114028_bib37","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejca.2024.114028_bib38","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"Stroud","year":"2019","journal-title":"J Oncol Pharm Pr"},{"key":"10.1016\/j.ejca.2024.114028_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000842","article-title":"Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition","volume":"8","author":"Laino","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2024.114028_bib40","doi-asserted-by":"crossref","first-page":"S869","DOI":"10.1016\/j.annonc.2021.08.1425","article-title":"1040O Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma","volume":"32","author":"Weber","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114028_bib41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jdv.16889","article-title":"European dermatology forum: updated guidelines on the use of extracorporeal photopheresis 2020 \u2013 Part 2","volume":"35","author":"Knobler","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2024.114028_bib42","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1111\/jdv.16890","article-title":"European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1. J Eur","volume":"34","author":"Knobler","year":"2020","journal-title":"Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2024.114028_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02207","article-title":"Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory\/Resistant Graft-Vs.-host disease without hampering anti-viral\/Anti-leukemic Effects","volume":"9","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2024.114028_bib44","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8118.1","article-title":"Extracoporeal photopheresis treatment of acute graft-versus-host disease following allogeneic haematopoietic stem cell transplantation","volume":"5","author":"Flinn","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.ejca.2024.114028_bib45","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114028_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15113041","article-title":"Better late than never: the impact of steroidal treatment on the outcome of melanoma patients treated with immunotherapy","volume":"15","author":"Bar-Hai","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2024.114028_bib47","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-20-3449","article-title":"Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial","volume":"27","author":"Montfort","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924006841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924006841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T01:35:18Z","timestamp":1714786518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924006841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":47,"alternative-id":["S0959804924006841"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114028","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114028"}}